The clinical faculty of the Division of Liver Diseases currently includes Drs. Nancy Bach, Meena Bansal, Norbert Brau, Charissa Chang, Scott Friedman, Douglas Dieterich, Hussien El-Siesy, Josep Llovet, Lawrence Liu, Patricia Lopez, Joseph Odin, and Thomas Schiano. All faculty participate in a cooperative enterprise that combines the care of a large and challenging population of patients with liver disease with close collaboration with investigators in other departments, such as Drs. Swan Thung and Isabel Fiel from Pathology, and Drs. Jonathan Bromberg, Myron Schwartz, Sukru Emre, and other members of the liver transplant surgical team (see Recanatic-Miller Transplant Institute).

The investigative interests of the Liver Diseases faculty reflect the breadth of Mount Sinai's patient population and the diverse venues in which these patients are cared for, including the Faculty Practice suite, The Mount Sinai Hospital Liver Clinic, clinics associated with the liver transplant program, and satellite offices in Englewood and Monmouth, New Jersey. Shared clinical research interests include the diagnosis and management of chronic hepatitis, especially that resulting from infection with the hepatitis B and C viruses; diagnosis and treatment of hepatic fibrosis, acute liver failure, alcoholic liver disease, drug-induced toxicity including TPN-related liver disease, fatty liver disease, porphyria and other genetic liver diseases, complications of chronic liver disease including ascites and hepatorenal syndrome, primary biliary cirrhosis, as well as complications of HBV and HCV infections, including hepatocellular carcinoma. At the same time, each faculty member has evolved an area of special expertise on which he or she has focused both their patient care activities and clinical investigative programs.

Nancy Bach, M.D.
Dr. Bach supervises a productive office-based program focused on clinical investigation in primary biliary cirrhosis (PBC), and participates in several national and international studies exploring the genetics and novel treatments of PBC.

Meena Bansal, M.D.
Dr. Bansal participates in clinical studies of fibrosis therapies and diagnostics, in addition to an active laboratory research program exploring the biology of matrix degradation in hepatic fibrosis, and mechanisms of fibrogenesis in patients co-infected with HCV and HIV.

Norbert Brau, M.D.
Dr. Brau's primary appointment is in the Division Infectious Diseases at the Bronx VA Hospital, has a secondary appointment in the Division of Liver Diseases and oversees a large clinical research program at the Bronx V in patients with either HCV or HCV/HIV co-infection.

Charissa Chang, M.D.
Dr. Chang recently appointed to the faculty, has a growing interest in hepatic complications of diabetes and obesity and is an investigator in several clinical trials exploring treatments of chronic liver diseases, including HCV and fibrosis.

Douglas Dieterich, M.D.
Dr. Dieterich is a seminal investigator in hepatic manifestations of HIV and recently was the lead author on a major study analyzing efficacy of anti-HCV therapy in patients co-infected with HIV, published in the New England Journal of Medicine.

Scott Friedman, M.D.
Dr. Friedman is an international authority in the pathogenesis, diagnosis and treatment of hepatic fibrosis, and is a leading figure in the establishment of clinical studies in this area. He is the Director of the Feld Fibrosis Program, which is a unique program evaluating novel therapeutics in hepatic fibrosis in partnership with a number of Biotech and Pharmaceutical companies. He is also an active investigator in the Mount Sinai Liver Cancer Program.

Lawrence Liu, M.D.
Dr. Liu has special expertise in defining treatments for hepatitis B and C in liver transplant patients. He is also an expert in management of patients with complications of liver transplantation.

Josep Llovet, M.D.
Dr. Llovet is jointly appointed to Mount Sinai and the University of Barcelona, is one of the world's leaders in the diagnosis and management of hepatocellular carcinoma (HCC) and is currently spearheading several national and international trials in HCC, in collaboration with faculty from the Departments of Surgery, Radiology and Pathology. As Research Director of the Mount Sinai Liver Cancer Program, he has been responsible for bringing several state-of-the-art trials to HCC.

Joseph Odin, M.D., Ph.D.
Dr. Odin leads a multidimensional research program exploring basic, translational and clinical studies of primary biliary cirrhosis (PBC). This includes participation as an investigator in several clinical trials, development of animal models, investigation of potential environmental precipitants of the disease, as well as the role of genetics.

Thomas Schiano, M.D.
Dr. Schiano has a particular clinical interest in the treatment of recurrent viral hepatitis after liver transplantation. He is involved in studies of passive immunoprophylaxis to prevent recurrent disease in patients undergoing transplant for hepatitis C-related end-stage liver disease. In addition, as a consequence of his having also been trained in clinical nutrition, he is exploring the association between nutrition and the health of the liver and the use of herbal and complementary medications for the treatment of liver disease.